Preliminary Final Report for Financial Year Ended 31 March 2016
The principal activity of the Group during the financial year was the ongoing clinical development of its lead drug candidate MIS416 to treat patients with secondary progressive multiple sclerosis (SPMS).
To view Report please download PDF attached:
